Tags Archive Navigation
icon
-
Media ReleaseNovartis annonce des changements au sein de son Comité de direction afin de soutenir ses priorités stratégiques
-
Media ReleaseNovartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an
-
Media ReleaseNovartis announces changes to the Executive Committee to support strategic priorities
-
Media ReleaseNovartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities
-
Media ReleaseNovartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren
-
Media ReleaseNovartis schliesst Vereinbarung zum Erwerb von AveXis Inc. für USD 8,7 Mrd ab, um Therapie der SMA zu transformieren und Position als führendes Gentherapie-und Neuroscience-Unternehmen auszubauen
-
Media ReleaseNovartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
-
Media ReleaseNovartis tender offer for AveXis commences
-
Media ReleaseNovartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
-
Media ReleaseNovartis provides update on proposed acquisition of AveXis
-
Media ReleaseSandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
-
Media ReleaseNovartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
Pagination
- ‹ Previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- › Next page